Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
SpaceX Price Predicted to Range Between $131 and $800. Where Will SPCX Land?

SpaceX Price Predicted to Range Between $131 and $800. Where Will SPCX Land?

BeInCryptoBeInCrypto2026/07/08 05:03
By:BeInCrypto
SpaceXs price targets now span a massive range. Wall Street analysts set targets from $131 to $800 as the IPO quiet period ended. Nineteen analysts published new ratings once the quiet period lifted for 23 underwriting banks behind SpaceXs IPO. The moves coincided with SpaceXs inclusion in the Nasdaq-100 index on Tuesday, July 7. The median target sits at around $250, a 56% jump from Mondays closing price. The High End of the Range Raymond James analyst Brian Gesuale set the Street-high target at $800. He compared SpaceX to railroads and the internet as foundational infrastructure. Citis John Godyn rated the stock a buy at $200. He called it a step toward a longer-term $900 target tied to Starship. Deutsche Banks Edison Yu and J.P. Morgans Doug Anmuth issued buy-equivalent ratings at $255 and $225. Morgan Stanleys Adam Jonas set a $300 base case. His range spans a $600 bull case and a $75 bear case. Despite its inclusion in the NASDAQ 100, SPCX has been trending down. Image Source: Trading View Fourteen of the 19 targets clustered between $200 and $250. That optimism follows heavy institutional demand. BlackRock placed a $5 billion order ahead of the companys $2 trillion debut last month. The Low End of the Range MoffettNathansons Julie Zhu set the Street-low target at $131, the sole holdout with a neutral rating that implies 18% downside. The firm called SpaceXs $30 trillion addressable market estimate absurd. It also questioned Musks plan to deploy 100 gigawatts of orbital compute by 2029. There is simply no credible financial model that can support what is at the time of this writing a roughly $2 trillion valuation. Our own certainly does not. Zhus team stopped short of a sell rating. The analysts argue investors are pricing SpaceX as an option on businesses that dont exist yet. It flagged regulatory scrutiny of SpaceXs launch dominance as the bigger long-term risk. That risk remains years away, the firm said. The nearly $700 gap between the highest and lowest targets leaves SpaceXs volatile stock at a crossroads. Starships next test this month could sway which camp proves right.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales